Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting
Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Professor Philip Molyneaux will present on the patient-reported outcomes from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)
Covered in this story
Analyst targets on Trevi Therapeutics Inc
- BMO Capital Markets: $13.3 → $36 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TRVI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Trevi Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.